小程序掃碼下單
本網站銷售的所有產品僅用于工業應用或者科學研究等非醫療目的，不可用于人類或動物的臨床診斷或者治療，非藥用，非食用。
Recombinant Human alpha-Galactosidase A, His (HEK293-expressed)
英文名：
Cas號：
Cas號：
檢測信息查詢
| 貨號 | 規格 | 貨期 | 庫存 | 價格 | 促銷價 | 訂購 |
| 1308133012-10 μg | 0 | ￥3600 | ||||
| 1308133012-50 μg | 0 | ￥11000 |
| 別 名 | |
| Cas號 | |
| M D L | |
| 分子式 | |
| 分子量 | |
| 產品參數 | |
| 性狀 | Recombinant Human alpha-Galactosidase A, His (HEK293-expressed)，一種在HEK293細胞中產生的重組人α-半乳糖苷酶A，在 C 末端有 His 標簽。Human alpha-Galactosidase A是負責從糖結合物中水解末端α-半乳糖基殘基的溶酶體外糖苷酶，是導致法布里病的有缺陷的酶。
Synonyms rHualpha-Galactosidase A, His; GLA; alpha-Galactosidase A ; 重組人α-半乳糖苷酶 A，His (HEK293-expressed) Species Human Source HEK 293 Accession P06280 Gene ID 2717 Molecular Weight 50-60 kDa AA Sequence LDNGLARTPT MGWLHWERFM CNLDCQEEPD SCISEKLFME MAELMVSEGW KDAGYEYLCI DDCWMAPQRD SEGRLQADPQ RFPHGIRQLA NYVHSKGLKL GIYADVGNKT CAGFPGSFGY YDIDAQTFAD WGVDLLKFDG CYCDSLENLA DGYKHMSLAL NRTGRSIVYS CEWPLYMWPF QKPNYTEIRQ YCNHWRNFAD IDDSWKSIKS ILDWTSFNQE RIVDVAGPGG WNDPDMLVIG NFGLSWNQQV TQMALWAIMA APLFMSNDLR HISPQAKALL QDKDVIAINQ DPLGKQGYQL RQGDNFEVWE RPLSGLAWAV AMINRQEIGG PRSYTIAVAS LGKGVACNPA CFITQLLPVK RKLGFYEWTS RLRSHINPTG TVLLQLENTM QMSLKDLLHH HHHH Biological Activity Data is not available. Appearance Solution Formulation Supplied as a 0.2 μm filter solution of 20 mM Tris-HCl, 150 mM NaCl, pH 8.0. Endotoxin Level <1 EU/μg, determined by LAL method. Reconstitution N/A Storage & Stability Recombinant Human alpha-Galactosidase A, His (HEK293-expressed) (rHualpha-Galactosidase A, His) is stored at -20°C. It is stable at 4°C for 1 week or -20°C for longer. It is recommended to freeze aliquots at -20°C or -80°C for extended storage. Shipping Shipping with dry ice. Background alpha-Galactosidase A (α-GAL, also known as α-GAL A) is responsible for the breakdown of α-galactosides in the lysosome. Defects in human alpha-Galactosidase A lead to the development of Fabry disease, a lysosomal storage disorder characterized by the buildup of α-galactosylated substrates in the tissues. alpha-Galactosidase A is an active target of clinical research: there are currently two treatment options for Fabry disease, recombinant enzyme replacement therapy and pharmacological chaperone therapy[2]. |
| 貯存 |
- Recombinant Human Alkaline Phosphatase, His (HEK293-expressed)
- Recombinant Human Allograft inflammatory factor 1, His
- Recombinant Human alpha-1-acid glycoprotein 2, His (HEK293-expressed)
- Recombinant Mouse Alpha-1-antitrypsin 1-1, His (HEK293-expressed)
- Recombinant Human alpha-Galactosidase A, His (HEK293-expressed)
- Recombinant Human alpha-Parvin, His
- Recombinant Human Ameloblastin, His (HEK293-expressed)
- Recombinant Human Amphoterin-Induced Protein 2, His (HEK293-expressed)
- Recombinant Human Amphoterin-Induced Protein 2, C-Fc (HEK293-expressed)
滬公網安備 31012002003054號